Fred M. Powell - 01 Jan 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role: Chief Financial Officer
Signature: /s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol: LVTX
Transactions as of: 01 Jan 2025
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2025, 09:20:03 UTC
Previous filing: 26 May 2022
Next filing: 18 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LVTX	Common Shares						65,000	01 Jan 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LVTX	Share Options (Right to Buy)							01 Jan 2025	Common Shares	195,000	$4.38	Direct	F1
holding	LVTX	Share Options (Right to Buy)							01 Jan 2025	Common Shares	120,950	$1.59	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	48,750 of the shares underlying the option vested on November 1, 2023 and the remainder vests in 36 equal monthly installments beginning on December 1, 2023, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F2	The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.